Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

COMPLETION OF ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR AND ADJUSTMENT TO COMPOSITION OF BOARD COMMITTEES

Completion of Election of Independent Non-Executive Director

麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the "**Company**") convened the 2025 First Extraordinary General Meeting (the "**EGM**") on 10 December 2025. The proposal regarding the nomination of Ms. Wang Zhiyao ("**Ms. Wang**") as a candidate for independent non-executive director ("**INED**") of the Company was considered and approved at the EGM. Accordingly, Ms. Wang was elected as an INED of the eleventh session of the board of directors (the "**Board**") of the Company. Her tenure will commence from the date of approval at the EGM and continue until the expiry of the term of office of the eleventh session of the Board.

Following the completion of the election of the INED, the proportion of independent directors within the members of the eleventh session of the Board is no less than one-third, which complies with the requirements of the relevant laws and regulations.

Reference is made to the announcement of the Company dated 10 November 2025 in relation to the proposed election of INED. The Board hereby provides the following supplementary disclosure pursuant to the requirements of Rule 13.51(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**"):

Ms. Wang's former Chinese full name was 王黔俊 (Wang Qianjun).

Save as disclosed above, there are no other matters in relation to the appointment of Ms. Wang that needs to be brought to the attention of the shareholders or The Stock Exchange of Hong Kong Limited, nor are there other information required to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules. Save as disclosed above, all other information contained in the circular and the announcement remains unchanged. This announcement serves as a supplement to the circular and the announcement and should be read together with them.

Election of Employee Representative Director

The Company convened the 2025 First Meeting of the Employee Representatives (the "**Employee Representatives Meeting**") on 10 December 2025. Following a qualification review of the candidate by the Nomination Committee of the Board, Ms. Ran Yongmei ("**Ms. Ran**") was duly elected through democratic procedures at the Meeting of the Employee Representatives as an employee representative director of the eleventh session of the Board.

Upon completion of the election of the employee representative director, Ms. Ran will join the current non-employee representative directors of the eleventh session of the Board to form the eleventh session of the Board of the Company. Her tenure will commence from the date of the Employee Representatives Meeting and continue until the expiry of the term of office of the eleventh session of the Board. The Company has entered into a service agreement with Ms. Ran.

The biography of Ms. Ran is as follows:

Ms. Ran, aged 42, obtained a bachelor's degree in Pharmacy from Chongqing Medical University (重慶醫科大學) in 2006. Ms. Ran previously worked at Shenzhen Sanofi Pasteur Biological Products Co., Ltd.* (深圳賽諾菲巴斯德生物製品有限公司), Shenzhen Salubris Pharmaceuticals Co., Ltd.* (深圳信立泰藥業股份有限公司), and Joincare Group Shenzhen Haibin Pharmaceutical Co., Ltd.*（健康元集團深圳市海濱製藥有限公司）. Ms. Ran joined the Company in January 2022 and currently serves as the Assistant to the President of the Company, concurrently holding the position of Deputy General Manager of Livzon MABPharm Inc.*（珠海市麗珠單抗生物技術有限公司）.

Upon her appointment, Ms. Ran will receive an annual director's remuneration of RMB 96,000 (before tax) during her term of office. Such director's remuneration is determined with reference to her duties and responsibilities to the Company, the Company's remuneration policy and the market salary range for such position.

Ms. Ran has confirmed that, save as disclosed above, she (i) does not hold any other position in the Company and any of its subsidiaries; (ii) has not held any directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (iii) has no other major appointment and professional qualification; (iv) does not have any other relationship with any director, senior management or substantial or controlling shareholder of the Company; and (v) does not have, or is not deemed to have, any interests in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, the Board is not aware of any other matter in relation to the appointment of Ms. Ran which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules and any other matter that needs to be brought to the attention of the shareholders of the Company.

Adjustment to Composition of Board Committees

In light of the changes in the composition of the Board, and in order to ensure the normal and orderly operation of the committees of the Board, the Company held the 30th meeting of the eleventh session of the Board on the same day. At the meeting, the "Proposal on Adjusting Members of Certain Special Committees of the Board" was considered and approved, whereby adjustments were made to the members of certain committees of the eleventh session of the Board. The composition of the committees of the eleventh session of the Board after the adjustment is as follows:

Board Committee	Composition
Audit Committee	Mr. Bai Hua (Chairman), Mr. Luo Huiyuan, Ms. Cui Lijie
Remuneration and Assessment Committee	Ms. Cui Lijie (Chairlady), Mr. Bai Hua, Mr. Tang Yanggang
Nomination Committee	Mr. Luo Huiyuan (Chairman), Ms. Cui Lijie, Mr. Tao Desheng
Environmental, Social and Governance Committee	Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang, Mr. Bai Hua, Ms. Cui Lijie, Ms. Wang Zhiyao
Strategy Committee	Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang, Mr. Tao Desheng

The term of office for the above members and chairmen/chairlady of the committees of the Board shall last until the expiry of the term of office of the eleventh session of the Board.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Liu Ning
Company Secretary

Zhuhai, China
10 December 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director of the Company is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

** For identification purpose only*